Valeant Reasons, Ackman Threatens In Latest Allergan Takeover Moves
This article was originally published in The Tan Sheet
Executive Summary
Valeant and activist investing partner Bill Ackman took opposite approaches to reports that Allergan may be pursuing Salix buyout as a defensive move to block a takeover. Acquiring Salix could put the cost of Allergan out of Valeant and Ackamn’s reach.